Last reviewed · How we verify
NCT07201064
A Study of SZ1003 Injection in Patients With Advanced Hepatocellular Carcinoma
EARLY_PHASE1 trial testing SZ1003 injection in Advanced Hepatocellular Carcinoma in 12 participants. Not yet recruiting.
30 March 2027
Quick facts
| Lead sponsor | Guangdong ProCapZoom Biosciences Co., Ltd. |
|---|---|
| Phase | EARLY_PHASE1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 12 |
| Start date | 25 September 2025 |
| Primary completion | 30 March 2027 |
| Estimated completion | 30 September 2027 |
Drugs / interventions tested
- SZ1003 injection — full drug profile →
Conditions studied
- Advanced Hepatocellular Carcinoma — all drugs for Advanced Hepatocellular Carcinoma →
Sponsor
Guangdong ProCapZoom Biosciences Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Hepatocellular Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study is a "3+3" dose-escalation, open-label, multiple-dose clinical trial.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07201064
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Hepatocellular Carcinoma
Currently open trials in the same condition.
- NCT07166406 — Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO- · Phase 3 · recruiting
- NCT07174570 — Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer · Phase 2 · recruiting
- NCT07227012 — Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatmen · Phase 1, PHASE2 · recruiting
- NCT06811116 — Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metasta · Phase 1, PHASE2 · recruiting
- NCT06789848 — Ligufalimab and Cadonilimab in Advanced Liver Cancers · Phase 2 · recruiting
Other Guangdong ProCapZoom Biosciences Co., Ltd. trials
Trials by the same sponsor.
- NCT07243366 — Allogeneic CD19-CAR-NK Cells in Patients With Refractory Myasthenia Gravis · EARLY_PHASE1 · not yet recruiting
- NCT07192666 — Exosomes in Patients With Ocular Involvement of Sjögren's Syndrome · EARLY_PHASE1 · not yet recruiting
- NCT07185139 — MSCohi-O Lenses for Ocular Involvement in Sjögren's Syndrome · EARLY_PHASE1 · not yet recruiting
- NCT06952114 — A Study of Stem Cells Lenses in the coGVHD Subjects · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07201064 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Guangdong ProCapZoom Biosciences Co., Ltd.
- Last refreshed: 1 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07201064.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing